YL-17231, oral panRAS inhibitor

YL-17231 is a clinical-stage panRAS inhibitor that blocks RAS signaling broadly against tumor mutations in KRAS, NRAS, HRAS, and amplified KRAS. Two Phase1 dose escalation clinical trials are exploring the safety and efficacy of YL-17231 in patients with KRAS, NRAS, or HRAS mutations.

Clinical Trials

NCT06096974, Phase 1 dose escalation trial enrolling in U.S.

NCT06078800, Phase 1 dose escalation trial enrolling in China